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Introduction: Drug interactions could account for 1% of hospitalizations in the
general population and 2–5% of hospital admissions in the elderly. However, few data
are available on the drugs concerned and the potential severity of the interactions
encountered. We thus first aimed to estimate the prevalence of dispensings including
drugs Contraindicated or Discommended because of Interactions (CDI codispensings)
and to identify the most frequently involved drug pairs. Second, we aimed to investigate
whether the frequency of CDI codispensings appeared higher or lower than the
expected for the drugs involved.
Methods: We carried out a study using a random sample of all drugs dispensings
registered in a database of the French Health Insurance System between 2010 and
2015. The distribution of the drugs involved was described considering active principles,
detailing the 20 most frequent ones for both contraindicated or discommended
codispensings (DCs). To investigate whether the frequency of CDI codispensings
appeared higher or lower than the expected for the drugs involved, we developed a
specific indicator, the Drug-drug interaction prevalence study-score (DIPS-score), that
compares for each drug pair the observed frequency of codispensing to its expected
probability. The latter is determined considering the frequencies of dispensings of the
individual drugs constituting a pair of interest.
Results: We analyzed 6,908,910 dispensings: 13,196 (0.2%) involved contraindicated
codispensings (CCs), and 95,410 (1.4%) DCs. For CCS, the most frequently involved
drug pair was “bisoprolol+flecainide” (n = 5,036); four out of five of the most represented
pairs involved cardiovascular drugs. For DCS, the most frequently involved drug pair was
“ramipril+spironolactone” (n = 4,741); all of the five most represented pairs involved
cardiovascular drugs. The drug pair involved in the CC with the highest score value was
“citalopram+hydroxyzine” (DIPS-score: 3.7; 2.9–4.6); that with the lowest score was
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“clarithromycin+simvastatin” (DIPS-score: 0.2; 0.2–0.3). DIPS-score median value was
0.4 for CCs and 0.6 for DCs.
Conclusion: This high prevalence of CDI codispensings enforces the need for
further risk-prevention actions regarding drug-drug interactions (DDIs), especially
for arrhythmogenic or anti-arrhythmic drugs. In this perspective, the DIPS-score
we develop could ease identifying the interactions that are poorly considered by
clinicians/pharmacists and targeting interventions.
Keywords: drug interactions, pharmacoepidemiology, medication errors, claim database, antiarrhythmic drugs
INTRODUCTION
Drug-drug interactions occur when the effects of one drug are
modified by the concomitant use of a second drug (Magro
et al., 2012). They constitute an important cause of adverse drug
reactions that are mostly predictable and avoidable (Seymour and
Routledge, 1998). Their prevention remains however complex
in clinical practice as the number of drugs that can potentially
interact is high. Additionally, the tools allowing to identify
coprescriptions/codispensings at-risk for interactions appear
difficult to use in clinical/officinal practice (van der Sijs et al.,
2006; Payne et al., 2015; Zheng et al., 2018). Depending on
studies, DDIs are estimated to cause 2–5% of hospital admissions
in elderly patients (Becker et al., 2007; Olivier et al., 2009;
Bénard-Laribière et al., 2015), and 1% of hospital admissions
in the general population (Dechanont et al., 2014). Nowadays,
the demographic and epidemiological transitions have led in a
growing proportion of the population being aged and presenting
with chronic comorbidities (Global Burden of Disease Study,
2015). This aging population is expected to result in an important
use of drugs, and a high prevalence of polypharmacy and
chronic polypharmacy (Haider et al., 2007; Nobili et al., 2011;
Maher et al., 2014). Polypharmacy is defined by the World
Health Organization as “the administration of many drugs at
the same time or the administration of an excessive number of
drugs” and continuous polypharmacy is limited to medications
taken for prolonged and regular periods (Fincke et al., 2005).
As the latter is the most important risk factor for DDIs, it
is likely that the populational exposure to the risk conveyed
by these deleterious drug associations will rise in the future,
except if dedicated interventions succeed to constrain it (Guthrie
et al., 2015; Stoll and Kopittke, 2015). If the overall impact and
health burden represented by DDIs is difficult to assess given
the wide heterogeneity of the adverse events they can induce
(Lopez-Gonzalez et al., 2009; Aronson, 2015), the populational
exposure to the risk of DDIs can conversely be estimated and
characterized by identifying codispensings of drug pairs that
are contraindicated or discommended, and by describing which
of such drug pairs are frequently codispensed despite their
concomitant use is advised against.
Abbreviations: CCs, contraindicated codispensings; CDI Codispensings,
codispensings contraindicated and discommended because of interactions; DCs,
discommended codispensings; DDIs, drug-drug interactions; DIPS-score, drug
interaction prevalence study-score; EGB, Echantillon Généraliste des Bénéficiaires.
To date, most studies have investigated DDIs in an in-hospital
setting, and little is not regarding the specificities of DDIs
encountered in out-hospital prescriptions. Moreover, on the
studies performed have mostly considered specific populations,
either in terms of comorbidies, or countries (Tulner et al., 2008;
Chatsisvili et al., 2010; Marzolini et al., 2010; van Leeuwen et al.,
2013; Dirin et al., 2014). Data that could be extrapolated to the
general out-hospital are thus very limited.; the main study we
identified conducted from the general population estimates that
0.5% prescriptions contain a contraindicated drug combination,
and 7% a clinically significant but controllable drug combination
(Toivo et al., 2016).
At all ends, none of these intended to evaluate prescribers’
potential knowledge of interactions or their willingness to avoid
associating contraindicated interacting drugs.
In this context, we first aimed to characterize the
Contraindicated or Discommended because of Interactions
(CDI codispensings) that could be identified from prescriptions
performed in an out-hospital setting. Second, we aimed to
investigate to what extent the frequencies of these CDIs could
reflect their potential avoidance by prescribers.
MATERIALS AND METHODS
Data Source and Study Population
This study was conducted using claims data from the EGB
database, a 1/97th dynamic age- and sex-representative sample of
the population covered by the French national healthcare system.
Briefly, EGB contains individual and anonymous data for 670,000
persons on demographic data such as gender, age and dates of
death. It also contains comprehensive data on outpatient drug
dispensing, including the dose and the quantity of the drugs
dispensed, the date of the dispensing and the characteristics
of the prescriber (Bezin et al., 2017). No information is
available in EGB concerning drugs that are not reimbursed
by the French national healthcare system, inpatient drugs, and
over-the-counter drugs.
In this study, a random sample of 100,000 patients who had
received at least one drug dispensing was constituted for each
quarter between 01/01/2010 and 31/12/2015. The randomization
was carried out used random numbers generator. For each
patient, all drug dispensed during the quarter of interest were
considered. Thus, the same patient was able to contribute to
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several drug dispensings. These drug dispensings was defined
as one to n drugs delivered by a pharmacist to a patient
on the same day.
Codispensings Contraindicated and
Discommended Because of Interactions
(CDI Codispensings)
Codispensings contraindicated and discommended because of
interactions were determined using the national thesaurus
elaborated by the French Medicines Agency (Agence Nationale
de Sécurité du Médicament et des produits de santé, ANSM).
This document entitled “Thésaurus des interactions” lists the
DDIs that are considered clinically meaningful either on a
drug class level or an individual drug level; its quality has
been internationally recognized1. This thesaurus provides thus
to health professionals an official source of information about
the main clinically meaningful DDIs (i.e., about 50,000 pairs
of drugs), with warnings on the risks they can convey and
recommendations for their management. DDIs are classified into
four categories: “to take into account,” “needing cautious use,”
“discommended,” or “contraindicated.”
Although its PDF format makes it difficult to be used in
routine practice by prescribers, the French thesaurus is often
mentioned as a main source by clinical decision support systems.
Moreover, this thesaurus constitutes an official and powerful tool
for the study of the populational exposure to the risk of DDIs
from medico-administrative databases.
To use this thesaurus we developed an R package to extract
the text from the PDF file and structured its content into a
more machine readable format (CSV)2. Because this thesaurus is
updated every year we used the thesaurus version corresponding
for each year. Using this thesaurus on our data set, we have
identified, within all dispensings, DDIs associated to the highest
level of risks for patients, i.e., those related to “discommended”
and “contraindicated” drug concomitant uses. For each quarter,
the prevalence of CCs and DCs was defined as the total number of
drug pairs contraindicated or discommended among our patient
sample. The proportion represented by a given drug pair within
all identified contraindicated/discommended codispensing was
estimated by reporting this number over the total number of
dispensings in which a codispensing of contraindicated (or
discommended) drugs has been identified.
Statistical Analysis
The prevalence of dispensing and the corresponding 95%
confidence interval was estimated for each pair of CDI
codispensed drugs and for each quarter of analysis from the
random sample. This prevalence was then extrapolated to
the French population using the annual demographic data
provided by the French National Institute for Statistics and
Economic Studies (Institut National de la Statistique et des
Etudes Economiques, INSEE)3. For this extrapolation, we have
1http://ansm.sante.fr/Dossiers/Interactions-medicamenteuses/Interactions-
medicamenteuses (accessed Aug 2018).
2https://github.com/scossin/IMthesaurusANSM (accessed Aug 2018).
3https://www.insee.fr/fr/statistiques/serie/000436387 (accessed Aug 2018).
taken into account the proportion of drug users in the
complete EGB, which is supposed to be representative of the
general population.
A measure of association we denominated the DIPS-score was
calculated for each pair of CDI codispensed drugs to determine
whether these drugs are more commonly used together or
not. The DIPS-score show if the prevalence of this pair was
irregular considering the frequency of dispensing of the two
drugs concerned. Considering the expected probability of a
codispensing of two drugs as the product of the proportion
of all dispensings represented by each of these drugs in our
sample. The DIPS-score corresponded to the ratio between
the observed proportion of codispensing of the drugs to this
expected probability. In theory, CDI codispensed drugs should
have a DIPS-score <1, as they are expected to be prescribed
concomitantly much less frequently than might be expected with
respect to their individual frequency of prescription. The 95%
Confidence Interval (95% CI) was estimated using the formula
allowing to compute a 95% CI for risk ratio under the hypothesis
of a normal distribution4.
The list of the twenty CCs and DCs most frequently found
over the entire study period and their corresponding DIPS-score
was studied in detail.
Analyses were performed using SAS R© version 9.4 (SAS
Institute Inc., Cary, NC, United States) and R version 3.2.3 (R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Globally, the population considered in the random samples had
a median age of 44.5 years (interquartile range: 24–63) and
including 44.2% of male. A total of 6,908,910 drug dispensings
was observed over the study period; among these, 13,196 implied
CCs (0.2%; 95% CI: 0.2–0.2%) and 95,410 DCs (1.4%; 95%
CI: 1.4–1.4%). Results by quarters over the study period and
extrapolation to the overall French population are presented in
Figure 1. According to these extrapolations, the number of CCs
by quarter, rounded in thousands, fluctuated between 143,000
(95% CI: 126,000–160,000) and 490,000 (95% CI: 460,000–
522,000), and the number of DCs by quarter fluctuates between
1,689,000 (95% CI: 1,635,000–1,744,000) and 2,210,000 (95% CI:
2,146,000–2,273,000).
Altogether, the different drug pairs involved in CDI
codispensings consisted of 254 drug pairs for CCs and 1,111 drug
pairs for DCs. The risk of CDI codispensing for each drug pair
was studied using an ad hoc developed indicator. This indicator
(DIPS-score) compares, for a given drug pair, the observed
frequency of codispensing to its expected probability. The mean
DIPS-score associated to CCs was 1.6 (median: 0.4; interquartile
range: 0.2–1.3); it was 8.8 for DCs (median: 0.6; interquartile
range: 0.2–1.8). Means exceeded medians because of extreme
high values: DIPS-score max was 87.8 among contraindicated
4Boston University School of Public Health: http://sphweb.bumc.bu.edu/otlt/
MPH-Modules/BS/BS704_Confidence_Intervals/BS704_Confidence_Intervals8.
html (accessed Dec 2018).
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FIGURE 1 | Number of observed contraindicated codispensings (CCs) and discommended codispensings (DCs) by quarter and extrapolation to the overall
population with 95% CI.
drug pairs and 2,700 among discommended pairs. These extreme
values were found for drugs rarely prescribed, which limited the
precision of DIPS-score estimations (Figure 2).
Table 1 shows the prevalence observed for the 20 drug pairs
most frequently identified in CCs, together with the estimated
value of the associated DIPS-score and its 95% CI. The drug pair
involved in the most frequent CC was bisoprolol+flecainide for
which 5,036 codispensings were identified, which corresponded
to 38% of all identified CCs. The drug pair involved in the CC
with the highest DIPS-score value was citalopram+hydroxyzine
(3.7; 95% CI: 4.6–2.9); that associated with the lowest one was
clarithromycin+simvastatin (0.2; 95% CI: 0.2–0.3).
Table 2 shows the prevalence observed for the 20 most
frequently identified drug pairs involved in DCs, together
with the estimated value of the associated DIPS-score and its
95% CI. The drug pair involved in the most frequent DC
was ramipril+spironolactone for which 4,741 codispensings
were identified; this corresponded to 5% of all identified
DCs. The drug pair involved in the DC with the highest
DIPS-score was eplerenone+ramipril (18.1; 95% CI: 22.6–14.5);
that associated with the lowest one was ibuprofen+ketoprofen
(0.2; 95% CI: 0.2–0.3).
Distributions of the DIPS-score values for the 20 most
frequent CCs and DCs are presented in Figure 3. For CCs,
the prevalence was generally lower than for DCs, and the value
of the associated DIPS-score more likely to be lower than 1.
An exception was noted for the contraindicated “bisoprolol +
flecainide” combination which presented with high values in
terms of prevalence and DIPS-score value with regards to the
distribution of this score for CCs (Table 1).
DISCUSSION
Key Findings
According to our study, 140,000–500,000 dispensings of drugs
would imply the concomitant delivery of contraindicated drugs
each quarter in France; these numbers would be of 1,700,000
and 2,200,000 for discommended drug associations. The drugs
mostly involved in CDIs were cardiovascular drugs with
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FIGURE 2 | The 254 contraindicated and 1,111 discommended drug pairs by prevalence and DIPS-score.
TABLE 1 | The twenty most frequently identified drug pairs involved in
contraindicated codispensings over the study period.
Prevalence Proportion DS∗
Drug A Drug B (n = 13,196) (%) (95% CI)
Bisoprolol Flecainide 5,036 37.9 3.6 (3.4–3.9)
Potassium Spironolactone 1,153 8.7 2.0 (1.8–2.2)
Flecainide Nebivolol 1,058 8.0 2.0 (1.8–2.2)
Flecainide Metoprolol 421 3.2 2.4 (2.0–2.9)
Domperidone∗∗ Escitalopram 404 3.0 0.5 (0.4–0.6)
Escitalopram Hydroxyzine 346 2.6 3.2 (2.8–3.6)
Fluoxetine Metoprolol 220 1.7 1.2 (1.0–1.4)
Clarithromycin Simvastatin 172 1.3 0.2 (0.2–0.3)
Bisoprolol Propafenone 168 1.3 1.3 (1.0–1.6)
Amiloride Spironolactone 167 1.3 1.1 (0.9–1.4)
Amiodarone Domperidone 124 0.9 0.4 (0.3–0.5)
Amiloride Potassium 121 0.9 1.7 (1.2–2.2)
Amiodarone Cyamemazine 112 0.8 0.5 (0.4–0.6)
Methotrexate Trimethoprime 110 0.8 2.6 (1.8–3.8)
Citalopram Hydroxyzine 106 0.8 3.7 (2.9–4.6)
Citalopram Domperidone 99 0.7 0.5 (0.4–0.6)
Sotalol Sulpiride 92 0.7 2.8 (1.9–4.1)
Amiodarone Sotalol 87 0.7 0.4 (0.3–0.5)
Cyclosporine Rosuvastatin 86 0.6 1.3 (0.9–1.7)
Domperidone Sotalol 85 0.6 0.3 (0.3–0.4)
∗DS, DIPS-score. ∗∗Drug pairs in italic correspond to those for which the observed
prevalence is lower than expected (upper 95% CI < 1).
antiarrhythmic/arrhythmogenic properties and psychotropic
drugs; the other identified involved drugs were very various.
The important variations according to time depended both on
changes in drug use and on changes in the listing of CDIs
considered clinically relevant in the reference we used, and
that is updated twice a year. However, overall, the global trend
observed for the prevalence of these CDIs showed with an
increasing trend from 2013 onward. If this can relate to the
TABLE 2 | The twenty most frequently identified drug pairs involved in
discommended codispensings over the study period.
Prevalence Proportion DS∗
Drug A Drug B (n = 95,410) (%) (95% CI)
Ramipril Spironolactone 4,741 5.0 3.1 (3.0–3.3)
Perindopril Spironolactone 4,676 4.9 2.4 (2.2–2.5)
Bisoprolol Rilmenidine 4,012 4.2 3.4 (3.1–3.6)
Spironolactone Valsartan 3,150 3.3 1.8 (1.7–1.9)
Candesartan Spironolactone 2,542 2.7 2.0 (1.8–2.1)
Nebivolol Rilmenidine 2,413 2.5 5.3 (4.8–5.9)
Irbesartan Spironolactone 2,267 2.4 1.4 (1.3–1.5)
Valproic acid Lamotrigine 1,863 1.9 17.7 (14.5–21.5)
Olmesartan Spironolactone 1,514 1.6 1.5 (1.4–1.6)
Eplerenone Ramipril 1,488 1.6 18.1 (14.5–22.6)
Cyamemazine Escitalopram 1,410 1.5 3.8 (3.5–4.2)
Perindopril Potassium 1,409 1.5 1.5 (1.4–1.6)
Losartan Spironolactone 1,289 1.4 1.9 (1.7–2.1)
Ibuprofen∗∗ Ketoprofen 1,247 1.3 0.2 (0.2–0.3)
Enoxaparin Ketoprofen 1,225 1.3 2.9 (2.6–3.2)
Diclofenac Ibuprofen 1,101 1.2 0.3 (0.3–0.3)
Irbesartan Potassium 1,062 1.1 1.4 (1.3–1.5)
Potassium Ramipril 1,056 1.1 1.5 (1.3–1.6)
Potassium Valsartan 1,023 1.1 1.2 (1.1–1.4)
Ezetimibe Fenofibrate 988 1.0 0.9 (0.8–1.0)
∗DS, DIPS-score.∗∗Drug pairs in italic correspond to those for which the observed
prevalence is lower than expected (upper 95% CI < 1).
adding of new information on contraindications, this could also
relate to the fact that the most concern drugs in age-related
diseases, which use is thus supposed to increase with population
aging. Yet, regarding at least contraindications, this number
would be expected to be much lower and to correspond to rare
situations of absolute necessity and therapeutic dead end. These
appealing result supports the need to increase DDIs prevention
and management. In this, they could help prioritizing the actions
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FIGURE 3 | The twenty most frequent contraindicated and twenty most frequent not discommended drug pairs by prevalence and DIPS-score with 95% CI.
that would need to be undertaken regarding to the prevalence
of codispensings highlighted for the different drug pairs and
to the health risk conveyed by the potential DDIs they carry
(Pirmohamed et al., 2004; Hines and Murphy, 2011; Montastruc
et al., 2012).
Compared to other studied performed in the general
population in an out-hospital settings, our results show with
lower estimates of prevalence (Merlo et al., 2001; Zwart-van
Rijkom et al., 2009; Toivo et al., 2016). Aside from the potential
differences that can exist between countries, the main reason
for these more conservative findings is that we restricted our
study to CDIs considered to be clinically meaningful. In the
study by Toivo et al. (2016) for instance, the authors used the
FASS classification. This classification lists DDIs according to 4
levels of potential DDIs, and seems more extensive than the one
we used but seems less selective than the French thesaurus. In
particular the especially for level C DDIs (clinically significant but
controllable drug combination) which corresponds to situations
were “interaction may modify the effect of the drug, controllable,
e.g., by dose adjustment”5.
If the issue is well-identified, it currently finds no simple
answer aside of enforced education and information. Studies that
focused on the interest of prescribing tools using clinical decision
support system indeed showed that the tools evaluated were
lacking of relevance for this specific objective (Nanji et al., 2017;
Zenziper Straichman et al., 2017). One of the main criticisms
emitted regarding these tools is related to their exhaustive
consideration of each and any potential interaction. Indeed, in the
prescription support they allow, interactions are treated equally
whatever their clinical relevance, which results in excessive
warning and, paradoxically, in alert fatigue and lack of efficacy
(Payne et al., 2015).
The last important result we provided is the estimation of
the statistical likelihood of the codispensings we performed
5FASS Allmänhet – Startsida: https://www.fass.se/LIF/startpage
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considering the individual frequency of dispensing of each
involved drug. This DIPS-score developed in this aim provided
results intrinsically consistent: its median value was lower for CCs
than for DCs (0.4 vs. 0.6) indicating that the first one were more
likely to be avoided by physicians, and the proportion of CCs
with a value of DIPS-score lower than 1 was much higher than
that of DCs. By allowing ranking interacting drug pairs according
to the potential unawareness or lack of perception of the risk
associated with their codispensing, this tool could provide helpful
information for the regulator.
Among the situations highlighted, some appeared of specific
importance. This was especially true for CCs or DCs presenting
with the higher prevalence, and for those presenting with a
prevalence far exceeding that expected for the drug-pair (i.e.,
associated with high DIPS-score values).
The prevalence of co-administration of QT prolonging
medications was high in our study, and found
associated to elevated values of DIPS-score (e.g., 3.7 for
citalopram+hydroxyzine). This could indicate that physicians
ignore or disagree with the importance of the associated risk
of ventricular arrhythmias including torsade de pointes and
sudden death (Wenzel-Seifert et al., 2011; Schlit et al., 2017).
Indeed, aside of this risk, the co-prescription of citalopram
and hydroxyzine appears consistent on a therapeutical basis.
It constitutes a combination of one antihistaminic indicated
in the treatment of anxiety to an antidepressant which would
appear rational in the context of the management of patients
with anxio-depressive disorders; there is however no specific
recommendation advocating for the concomitant use of these
drugs especially. If proven of real interest, the association would
at least deserve a close electrocardiographic monitoring of QT in
patients at the time each drug is initiated. If not, it would deserve
a clear action of communication owing to the nature of the
hazard risked and to the observed frequency of the co-delivery.
The importance of the prevalence of this coprescription at least
advocates for the elaboration of a guideline either recommending
not to use these drugs in combination for the management
of anxio-depressive disorders, either to do it with a specific
electrocardiographic monitoring of QT that would need to be
determined. This appears of specific importance as Schlit et al.,
among others, showed that concomitant treatment with drugs
known to induce arrhythmia was the greatest risk factor for QT
prolonging by hydroxyzine (Schlit et al., 2017).
Conversely, the results we found were in favor of a good
knowledge by prescribers of the DDI concerning clarithromycin
and simvastatin. This association is contraindicated as leading to
an increase in statin serum concentration and to a consecutive
rise in the risk of presenting with cytolytic hepatitis or
rhabdomyolysis (Page and Yee, 2014). For this pair constituted
of drugs frequently used in the population, the overall amount
of co-deliveries was high. However, it should have been much
higher owing to the individual frequencies of dispensings of
these drugs. Indeed, the DIPS-score estimated for the pair
was of 0.25, revealing the prevalence of the co-delivery was
approximately four times lower than expected. Interestingly,
both clarithromycin and simvastatin are named in full in
the interaction section of these drugs summary of product
characteristics. The fact that the interaction is well-identified
conversely to other for which interactions are specified using drug
class instead of individual drug names should be considered.
Limitations and Strengths
Amongst the drug-pairs for which results deserve a
special attention, those concerning beta-blocker and other
antiarrhythmic agents need to be discussed, as they can be
specifically affected by the limitations of the study we present.
Our estimations are based on an automated analysis of the
codispensings observed in the study population, disregarding
indication or patient background. As bisoprolol, for instance,
is contraindicated with class one antiarrhythmic agents (e.g.,
flecainide) only in patients with cardiac failure, these results
would need to be further explored. Contraindicated beta-blocker
and antiarrhythmic agents were indeed found to be by far the
most prevalent CCs, and to be coprescribed much more than
expected. Interestingly in the last version of the Thesaurus, that
was released in May 2018, these codispensings were no longer
considered contraindicated but only discommended.
Among DCs, the drug pairs most frequently found
were “ramipril+spironolactone” (5% of DCs) and
“perindopril+spironolatone” (4.9% of DCs). If these
codispensings are discommended to avoid hyperkalemia,
their prevalence cannot be thought to represent the ignorance of
the risk they carry. Indeed, it is likely that some patients in which
these drugs are associated benefit from a close monitoring of
kalemia. This was not evaluated in our study that only considered
dispensings data.
Our objective was to identify CCs and DCs that would
potentially result from a lack of knowledge of the risk
conveyed, in order to help targeting future information
campaigns/interventions aiming to minimize the risk associated
to CDI codispensings. In this aim, we only considered co-
prescriptions, and the proxy of such constituted by co-
deliveries. The result herein presented thus correspond to
an underestimated prevalence of concomitant use of drugs
Contraindicated or Discommended because of Interactions,
as they do not consider concomitant treatments that would
result from successive but overlapping dispensings. If willing
to estimate this overall prevalence, it would be needed to
individualize sequences and overlaps of dispensing in patients,
whatever the date of delivery. Additionally, as dealing with a
reimbursement database, OTC deliveries cannot be considered
for the estimation of the prevalence of concomitant treatments
for contraindicated or discommended drug pairs. This is another
factor of underestimation for the prevalence of use of drugs
Contraindicated or Discommended because of Interactions, that
however also not relate to a potential ignorance of the associated
risk by physicians.
A specific strength of this study was to use a probabilistic
method to allow evaluating to what extent drugs associations
could be though or avoided. If allowing thus to assess the burden
represented by each drug pairs amongst all situations at risk
of potential interactions, and those that could be reduced, this
study did not provide information on the adverse events actually
engendered. In this perspective, it would be adequately completed
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by a study investigating the adverse reactions reported for the
drug pairs herein identified. It would also be completed by
studies investigating whether DDIs were ignored or deliberately
overridden and considered to carry no or very weak risk with
regard to the expected benefits.
The question raised by this work advocates for further
development in studying CDIs in an out-hospital setting. DDIs
are always considered according to situations of use placing the
patient at-risk for an event, in the case the DDI would actually
result in a clinically meaningful modification of the drug effect.
To which extent the observed CDIs translate into clinical events
that impact on patients and public health is not yet clearly
quantified and should be investigated. Moreover, as this impact,
at least in terms of population health, would both clearly depend
on the frequency of exposure and on the baseline risk or frailties
of the exposed population, studying it especially in the elderly
would be of primary importance.
CONCLUSION
The prevalence of codispensings of drugs Contraindicated
or Discommended because of Interactions was found high.
It concerned a large amount of drug-pairs; if these were
heterogeneous, arrhythmogenic or antiarrhythmic drugs where
largely represented. Despite these results did not consider the
clinical consequences of these drug combinations, they provide
a conservative but credible estimate of the potential iatrogenic
burden of the DDIs as only codispensings related to clinically
meaningful DDIs were considered. Together with this prevalence
estimate allowing identifying which drug pairs were the most
often encountered amongst these codispensings at-risk, we
provided a tool, the DIPS-score, that could help identifying which
DDIs might be the most ignored by prescribers and, potentially,
identifying practices corresponding to new use of drugs.
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